Clinical implementation of the Humacyte human acellular vessel: implications for military and civilian trauma care.
The incidence of wartime vascular injury has increased and is a leading cause of mortality and mobidity. While ligation remains an option, current resuscitation and damage control techniques have resulted in vascular repair being pursued in more than half of wartime injuries. Options for vascular reconstruction are currently limited to autologous vein or synthetic conduits, choices which have not changed in decades, both of which have problems. Autologous vein is preferable but requires time to harvest and may not be available. Synthetic grafts are poorly resisent to infection and associated with thrombotic complications.Recognizing this capability gap, the U.S. Combat Casualty Care Research Program has partnered with academia and industry to support the development, and clinical introduction of a bioengineered human acellular vessel (HAV). This HAV has the potential to be an off-the-shelf conduit that is resistant to infection and incorporates well into native tissues. This report reviews the rationale of this military-civilian partnership in medical innovation and provides an update on the clinical use and ongoing study of this new vascular technology. LEVEL OF EVIDENCE: III; Therapeutic.